Jubiglim MV 1 Plus Tablet SR is a combination oral antihyperglycemic agent formulated to improve glycemic control in patients with type 2 diabetes mellitus. It contains Glimepiride 1mg, Metformin 500mg, and Voglibose 0.3mg, each contributing distinct mechanisms to regulate blood glucose levels. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing fasting and postprandial blood glucose. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption in the intestines, attenuating postprandial hyperglycemia. The sustained-release (SR) formulation ensures gradual drug release, promoting stable plasma concentrations and improved patient compliance. Jubiglim MV 1 Plus is indicated for patients inadequately controlled on diet and exercise alone or in combination with other antidiabetic agents. It is essential to monitor blood glucose levels regularly to adjust therapy appropriately and minimize the risk of hypoglycemia. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to any component. This combination therapy offers a comprehensive approach to managing hyperglycemia by targeting multiple pathophysiological defects in type 2 diabetes.